PND33 The Cost-Effectiveness of Disease Modifying Therapies for The Treatment of Relapsing-Remitting Multiple Sclerosis  by Bozkaya, D. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A283
Clinical efficacy, utilities and transition probabilities were derived from published 
studies. Resource costs were estimated from 656 individual patient level data from 
Adelphi 2012 UK patient dataset, using Irish costs, where possible. Time horizon 
was 20 years and patients were followed until death if it occurred earlier. Costs 
and outcomes were discounted at 4%. Both one-way and probabilistic sensitivity 
analyses were conducted.. RESULTS: The incremental cost-effectiveness ratio for 
LCIG vs. SOC was € 41,114/QALY (total costs LCIG vs. SoC are € 537,276 vs. € 465,716 
and QALYs are 4.72 vs. 2.98). LCIG is cost-effective at a payer threshold of € 45,000. 
The model is most sensitive to health state costs. CONCLUSIONS: LCIG is a cost-
effective option in treating APD patients in Ireland.
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OBJECTIVES: To compare the cost-effectiveness of current disease modifying thera-
pies (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS) in the 
US. METHODS: An economic model was created to predict the course of patients 
with RRMS following initiation of a DMT. Natalizumab (NAT), dimethyl fumarate 
(DMF), and peginterferon beta-1a (PEG), were compared with fingolimod (FIN), glati-
ramer acetate (GA, 40 milligrams thrice weekly), and interferon beta-1a (INT, 44 
micrograms thrice weekly), respectively. The Markov state transition cohort model 
predicted disease progression across RRMS Expanded Disability Status Scale [EDSS] 
states and for secondary-progressive (SPMS) EDSS states in 3-month cycles over a 
10-year time horizon. The patient cohort was at risk of death, relapse, or discontinu-
ation (due to reaching EDSS level 7, or following DMT-specific rates) in each cycle. 
Outcome measures were relapses, relapse-free time, MS progression, and progres-
sion and clinical disease activity-free years. Costs included drug, administration, 
monitoring, relapse, and EDSS state costs. Incremental cost-effectiveness ratios 
(ICERs) were estimated for each of the outcome measures. RESULTS: Costs ranged 
from $477,158 (DMF) to $526,667 (INT). NAT, DMF, and PEG were less expensive with 
equal, or better, outcomes. NAT and DMF were dominant (less costly and more 
effective) compared to FIN and GA, respectively, for all ICERs. PEG dominated INT 
on progression and clinical disease activity outcomes. Comparable relapse-related 
outcomes cost more than $30,000 with INT compared to PEG. Variability in drug 
costs and parameters that affected drug cost accrual (eg, discontinuation rates 
and the decision to drop out after SPMS conversion) had a considerable impact on 
ICERs. CONCLUSIONS: Results from this analysis suggest that the NAT, DMF and 
PEG are cost-effective DMT choices compared to FIN, GA, and INT, respectively. The 
actual impact to a particular plan will vary based on drug pricing and other factors 
affecting drug cost accrual.
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OBJECTIVES: To analyze cost effectiveness of amitriptyline and propranolol in the 
management of migraine METHODS: A total of 60 patients with migraine were 
enrolled, into the Prospective, observational, exploratory study based on the inclu-
sion and exclusion criteria. Migraine headache frequency, duration and used of over 
the counter drugs per month migraine headache pain score and headache impact 
test score were assessed and recorded at baseline by using a suitably designed ques-
tionnaire and headache impact test questionnaire. The patients were given either 
amitriptyline or propranolol . After the completion of one month of drug therapy 
score of patients were measured using the same questionnaire and in addition cost 
of prescription drugs and over the counter drugs were calculated.The effectiveness 
of treatment on patients was evaluated by comparing the mean scores before and 
after treatment by applying paired sampled T- test and independent sample test to 
compare means between the two treatment groups. Cost effectiveness analysis was 
done in terms of reduction of headache frequency per month before and after the 
treatment . RESULTS: The result showed that to prevent single migraine headache 
patient under amitriptyline group has to pay NRs.8.897 on the drugs (amitriptyline 
and analgesic)where patient under Propranolol group has to pay NRs.30.11 on the 
drugs (propranolol and analgesic) to prevent single migraine headache. In addi-
tion the study suggests using either amitriptyline or propranolol for treatment of 
migraine headache is same in terms of reduction of headache frequency and in 
terms of reduction of headache duration. However amitriptyline was found supe-
rior to propranolol in terms of reduction of headache impact test score and used of 
over the counter drugs. But propranolol was found to significantly lower headache 
pain score compare to amitriptyline. CONCLUSIONS: Amitriptyline is the most cost 
effective option when compared to propranolol in migraine.
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OBJECTIVES: Compare the cost-efectiveness (CE) of levodopa, pramipexole, rasagil-
ine and selegiline in patients with early Parkinson’s disease from the perspective 
of National Institute of Neurology and Neurosurgery (NINN) in Mexico. METHODS: 
We developed a CE model, that linked Unified Parkinson’s Disease Rating Scale 
(UPDRS) Parts II (activities of daily life) and III (motor) scores to disease progres-
sion and direct costs (drugs, medical appointments, adverse events, and labora-
tory studies), which were obtained of clinical records and unit cost of NINN. Data 
used in the model were obtained from clinical trials and we developed an indirect 
patients without CM ($1,756). There were more CM patients with accompanying pain 
at all levels (mild: 19.53% vs. 0.16%; moderate: 13.10% vs. 0.10%; severe: 16.20% vs. 
0.12%; all p< 0.0001). CONCLUSIONS: CM patients in the VHA population had sub-
stantial health care resource utilization, incurred higher costs and suffered worse 
pain compared to those without the disease.
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OBJECTIVES: To examine the health care resource utilizations and costs among 
migraine patients in the U.S. Medicaid population. METHODS: Migraine patients 
were identified (International Classification of Disease, 9th Revision, Clinical 
Modification [ICD-9-CM] diagnosis code 346) using Medicaid data from January 01, 
2009 through December 31, 2009. The first diagnosis date was designated as the 
index date, and patients were required to have at least a 1-year baseline (pre-index 
date) and 1-year follow-up (post-index date) period. A comparison cohort was cre-
ated for patients without a migraine diagnosis during the study period, using 1:1 
propensity score matching to control for age, region, gender and baseline Charlson 
Comorbidity Index score. The comparison cohort’s index date was chosen at ran-
dom to minimize selection bias. Patients in both cohorts were required to be age 
≥ 18 years and have continuous medical and pharmacy benefits 1-year pre- and 
post-index date. Study outcomes (health care resource utilizations and costs) were 
compared between the migraine and comparison cohorts. RESULTS: After applying 
PSM, 380,751 patients were assigned to each cohort, and baseline characteristics 
were well-balanced. A higher percentage of patients with migraines had inpatient 
stays (21.53% vs. 11.00%, p< 0.0001), other therapy (99.88% vs. 65.78%, p< 0.001) and 
pharmacy visit claims (90.52% vs. 48.35%, p< 0.0001), compared to those without a 
migraine diagnosis. The patients in the migraine cohort also incurred significantly 
higher other therapy ($4,111 vs. $2,312, p< 0.0001) and pharmacy visit costs ($1,074 
vs. $512, p< 0.0001) than those in the comparison cohort. CONCLUSIONS: Migraine 
patients incurred significantly higher costs and had higher health care resource 
utilizations than those without migraines.
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OBJECTIVES: Parkinson’s disease (PD) is a progressive disease associated with 
substantial economic and societal burden. Immediate-release (IR) carbidopa-levo-
dopa (CD-LD) is the gold standard in treatment for advanced PD patients. However, 
effectiveness of IR CD-LD diminishes with long-term treatment and is associated 
with increased “off” time (re-emergence of PD symptoms) and the advent of motor 
complications. CD-LD plus entacapone (CL+E) has produced some clinical improve-
ment over IR CD-LD alone. IPX066 is an extended-release oral formulation of CD-LD 
designed to address some of the limitations of IR CD-LD by rapidly attaining and 
maintaining therapeutic LD concentrations for a prolonged duration. The aim of 
the study was to evaluate the comparative cost-effectiveness of IPX066 against 
CL+E. METHODS: A Markov model was developed comparing IPX066 with branded 
and generic CL+E in the US market. Health states included ≤ 25% “off” time, > 25% 
“off” time, and dead. The model simulated a hypothetical patient’s progression over 
a 5-year period through these health states, with a 6-month Markov cycle length. 
Outcomes evaluated were total direct costs, quality-adjusted life years (QALYs), 
and incremental cost-effectiveness ratios (ICER). Dosing and efficacy data from 
a Phase 3 study comparing IPX066 and CL+E, average wholesale acquisition drug 
costs (RedBook), and published literature were utilized for this evaluation. Non-2014 
costs were inflated to reflect the 2014 value using the medical component of the 
Consumer Price Index. The discount rate employed was 3%. RESULTS: IPX066 was 
dominant over both branded and generic CL+E therapies, with ICERs of (-$166,044) 
and (-$75,920), respectively. On average, patients who received IPX066 experienced 
a 5.1% increase in QALYs (2.90) compared with patients who did not receive IPX066 
(2.76). IPX066 dominated the other two therapies throughout multiple sensitivity 
analyses, driven largely by improved effectiveness of IPX066. CONCLUSIONS: IPX066 
is likely to be a cost-effective therapy in patients with advanced PD.
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BACkgROUND: Parkinson’s disease (PD) is an incurable, progressive neurological 
disease, with primary symptoms impacting movement, walking and posture; that 
eventually become severely disabling. Advanced PD (APD) has a significant impact 
on Quality of Life (QoL) for patients, their carer’s/families. Levodopa/Carbidopa 
intestinal gel (LCIG) is indicated for the treatment of advanced levodopa-responsive 
Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when 
available combinations of Parkinson medications have not given satisfactory results. 
There are no published studies reporting the economic value of LCIG in treatment 
of patients with APD in Ireland. OBJECTIVES: Determine the cost-effectiveness of 
LCIG compared with Standard of care (SoC) for the treatment of APD patients in 
Ireland METHODS: A deterministic Markov model was used to evaluate LCIG vs. 
SoC in APD patients with severe motor fluctuations from an Irish health care per-
spective. The model simulated a cohort of 100 patients and redistributed them into 
disease-specific health states. Health states were defined by Hoehn & Yahr (H&Y) 
scale combined with amount of time in OFF-time. SoC comprised of standard oral 
therapy +/- sub-cutaneous apomorphine infusion and standard follow up visits. 
